Evidence map›Paper›PMID 34787822›Full record

ReviewAdvances in therapy2022

Value of Remission in Patients with Rheumatoid Arthritis: A Targeted Review.

Andrew J Ostor, Ruta Sawant, Cynthia Z Qi, Aozhou Wu, Orsolya Nagy, Keith A Betts

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advances in therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Review
  10. Article
  11. Observational
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Andrew J OstorCabrini Medical Center, Monash University and Emeritus Research, Melbourne, VIC, Australia.
Ruta SawantAbbVie, Inc., North Chicago, IL, USA.
Cynthia Z QiAnalysis Group, Inc., Boston, MA, USA.
Aozhou WuAnalysis Group, Inc., 333 S. Hope Street, 27th Floor, Los Angeles, CA, 90071, USA.
Orsolya NagyAbbVie, Inc., North Chicago, IL, USA.
Keith A BettsAnalysis Group, Inc., 333 S. Hope Street, 27th Floor, Los Angeles, CA, 90071, USA. keith.betts@analysisgroup.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The treat-to-target strategy, which defines clinical remission as the primary therapeutic goal for rheumatoid arthritis (RA), is a widely recommended treatment approach in clinical guidelines. Achieving remission has been associated with improved clinical outcomes, quality of life, and productivity. These benefits are likely to translate to reduced economic burden in terms of lower healthcare costs and resource utilization. As such, a literature review was conducted to better understand the economic value of remission. Despite the large heterogeneity found in RA-related economic outcomes across studies, patients in remission consistently had lower direct medical and indirect costs, less healthcare resource utilization, and greater productivity compared to those without remission. Remission was associated with 19-52% savings in direct medical costs and 37-75% savings in indirect costs. The economic value of remission should thus be considered in economic analyses of RA therapies to inform treatment and reimbursement decisions.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidCost-Benefit AnalysisEfficiencyHealth Care CostsHumansPatient Acceptance of Health CareQuality of LifeAntirheumatic AgentsDirect costEconomic benefitHealthcare resource utilizationIndirect costRemissionRheumatoid arthritisTreat-to-target

Identifiers

PMID34787822
PMCPMC8799574

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.